Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
2,248
datasets available to search
ShareScore release 0.9.0
Dataset results
2,248 results for “squamous cell carcinoma”
Gene expression landscape of cutaneous squamous cell carcinoma progression
<p>Data files associated with "Gene expression landscape of cutaneous squamous cell carcinoma progression" by Bencomo and Lee. </p><p>The README.md file has descriptions for each file.</p><p><strong>Funding support</strong>: This work was supported by a Scholar-Innovator Award from the Harrington Discovery Institute and a Discovery Boost grant from the American Cancer Society (CSL).</p>
Hormone receptors AR, ER, PR and growth factor receptor Her-2 expression in oral squamous cell carcinoma: Correlation with overall survival, disease-free survival and 10-year survival in a high-risk population
<p>Oral squamous cell carcinoma (OSCC) comprises most of head and neck neoplasms and is one of the highest-ranking and lethal cancers in Pakistan due to prevailing mouth habits. Growth and hormonal receptors act as prognostic markers and targets for therapy in some cancers, but their application in OSCC is largely unexplored. This study aimed to evaluate the expression of growth and hormonal receptors in OSCC patients and correlate it with 10-year, overall and disease-free survival. To achieve this objective, immunohistochemistry for Her-2, AR, ER and PR was performed on 100 formalin-fixed paraffin-embedded primary OSCC specimens. Receptor expression was correlated with mouth habits and clinicopathological features and patient survival was analyzed using Kaplan-Meier method and Cox regression univariate analysis. We observed that in 100 patients, there were 57 males and 43 females. Immunopositive Her-2 expression was observed in 21% of patients, AR in 13%, ER in 3% and 0% for PR. Patients with betel quid/areca nut mouth habits had significantly absent Her-2 expression (P=0.035). Also, Her-2 negative patients were also negative for AR expression (P=0.002). Her-2 positive patients had poor 10-year survival (P=0.041). A trend of low survival and high recurrence rate was observed in AR positive patients, but this was not significant (P=0.072). No statistically relevant correlations were seen in the case of ER and PR. In conclusion, Her-2 may be a valuable marker for predicting long-term prognosis of OSCC patients.</p>
The role of Cornulin (CRNN) in the progression of cutaneous squamous cell carcinoma involving AKT activation in SCL-1
<p>Cutaneous squamous cell carcinoma (cSCC) is a prevalent type of skin cancer that has been on the rise in recent times, particularly among older individuals. Cornulin (CRNN) is increasingly recognized as an oncogene involved in developing various types of tumors. However, the precise contribution to cSCC remains unclear. Our study observed a significant increase in CRNN expression in cSCC samples compared to healthy skin. CRNN expression in the SCL-1 cell line derived from cSCC was reduced, leading to a halt in cell growth during the transition from the G1 phase to the S phase. This reduction inhibits cell division, promotes cell death, and decreases cell invasion and migration. CRNN overexpression has been found to enhance cell growth and prevent cells from undergoing natural cell death, and the cancer-promoting effects of CRNN are linked to AKT activation. Using a mouse xenograft model, we demonstrated that the inhibition of CRNN led to a decline in cSCC tumor growth in a living organism, providing evidence of CRNN’s involvement in cSCC occurrence and development. This study establishes a foundation for evaluating the effectiveness of CRNN in treating cSCC, enabling further investigation in this area</p>
The effect of extracellular vesicles derived from oral squamous cell carcinoma on the metabolic profile of oral fibroblasts
<p><span>Oral cancer is one of the most common forms of head and neck cancers. Oral squamous cell carcinoma (OSCC) accounts for more than 90% of the oral malignancies. The molecular pathogenesis of OSCC is complex as it involves altered expression of specific genes and proteins, but also comprises changes in metabolic processes. It is suggested that extracellular vesicles (EVs) released by cancer cells may contribute to cancer development and metastasis by recruiting and changing phenotype of normal cells that surround the tumor. The aim of the project was to characterize the effect of OSCC EVs on the metabolic profile of normal oral fibroblasts (NOFs). Targeted </span><span>liquid chromatography-mass spectrometry metabolic profiling was performed on control cells and NOFs exposed to OSCC EVs for 24 and 48 h. Analysis of detected metabolites revealed that OSCC EVs affected NOFs the most after 24 h of exposure. Among metabolites that were significantly altered at 24 h, </span><span>pyruvate, ATP, UTP, coenzyme A, and dihydroxyacetone phosphate were upregulated, while fatty acids such as nervonic acid, linoleate, oleate, palmitoleic acid, and docosahexaenoic acid were downregulated. These findings were supported by Western blotting of pyruvate kinase M2 (PKM2). The metabolic pathways of glycolysis, </span><span>citric acid cycle, and </span><span>amino acid metabolism were enriched, suggesting that OSCC EVs cause phenotype switch in NOFs that may contribute to </span><span>acquiring</span><span> a pro-tumorigenic phenotype.</span></p>
Exploring NSD3 Driven Gene Expression Profiles in Lung Squamous Cell Carcinoma
<p><strong>SGC Open Notebook Project to Characterize the HMTase NSD3</strong></p> <p><strong>Exp026 Objective:</strong> NSD3 is frequently amplified as part of the 8p11-12 focal amplification in several types of cancer. Here we set out to explore the gene expression profiles of NSD3 amplified versus non-amplified lung squamous cancer samples from the TCGA. However, because this event takes place in the context of a focal amplification we will also compare samples with high versus low NSD3 expression. The goal of this experiment is to identify putative oncogenic signalling pathways NSD3 may regulate, as well as inform on the biological role of this protein in the context of gene expression. </p>
TCGA Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (CESC) Clinical Data
<p><strong>Abstract:</strong></p> <p>The Cancer Genome Atlas (TCGA) was a large-scale collaborative project initiated by the National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI). It aimed to comprehensively characterize the genomic and molecular landscape of various cancer types. This dataset includes curated survival data from the Pan-cancer Atlas paper titled <a href="http://www.cell.com/cell/fulltext/S0092-8674(18)30229-0">"An Integrated TCGA Pan-Cancer Clinical Data Resource (TCGA-CDR) to drive high quality survival outcome analytics"</a>. The paper highlights four types of carefully curated survival endpoints, and <a href="http://www.cell.com/action/showFullTableImage?isHtml=true&tableId=tbl3&pii=S0092867418302290">recommends the use of the endpoints of OS, PFI, DFI, and DSS for each TCGA cancer type</a>. The dataset also includes phenotypic information about CESC. The Sample IDs are unique identifiers, which can be paired with the gene expression dataset. </p> <p><strong>Inspiration:</strong></p> <p>This dataset was uploaded to UBRITE for GTKB project. </p> <p><strong>Instruction:</strong></p> <p>The survival and phenotype data were merged into one file. </p> <p><strong>Acknowledgments:</strong></p> <p>Goldman, M.J., Craft, B., Hastie, M. et al. Visualizing and interpreting cancer genomics data via the Xena platform. Nat Biotechnol (2020). https://doi.org/10.1038/s41587-020-0546-8</p> <p>Liu, Jianfang, Caesar-Johnson, Samantha J. et al. An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics. Cell, Volume 173, Issue 2, 400 - 416.e11. <a href="https://doi.org/10.1016/j.cell.2018.02.052">https://doi.org/10.1016/j.cell.2018.02.052</a></p> <p>The Cancer Genome Atlas Research Network., Weinstein, J., Collisson, E. et al. The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet 45, 1113–1120 (2013). https://doi.org/10.1038/ng.2764</p> <p><strong>U-BRITE last update: </strong>07/13/2023</p>
Sarcopenia index predicts short-term prognosis of head and neck squamous cell carcinoma
<p>Dataset of "Sarcopenia index predicts short-term prognosis of head and neck squamous cell carcinoma"</p>
Window Study of Nivolumab With or Without Ipilimumab in Squamous Cell Carcinoma of the Oral Cavity
ClinicalTrials.gov study NCT02919683. IPD Sharing: NO. Countries: 1. Publications: 2.
Re-irradiation With Fractionated Stereotactic Radiosurgery Plus Cetuximab in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck
ClinicalTrials.gov study NCT01104922. IPD Sharing: NO. Countries: 1. Publications: 1.
Anti-PD-L1/TGF-beta Trap (M7824) Alone and in Combination With TriAd Vaccine and N-803 for Resectable Head and Neck Squamous Cell Carcinoma Not Associated With Human Papillomavirus Infection
ClinicalTrials.gov study NCT04247282. IPD Sharing: YES. Countries: 1. Publications: 3.
Temsirolimus (Torisel®) and Erlotinib (Tarceva®) in Platinum-Refractory/Ineligible, Advanced, Squamous Cell Carcinoma
ClinicalTrials.gov study NCT01009203. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Testing Afatinib in Combination With Pembrolizumab in Patients With Squamous Cell Carcinoma of the Lung
ClinicalTrials.gov study NCT03157089. IPD Sharing: UNDECIDED. Countries: 5. Publications: 2.
Reconstruction of Cervical Lymphatic System During Head and Neck Squamous Cell Carcinoma Surgery
ClinicalTrials.gov study NCT06815705. IPD Sharing: YES. Countries: 1. Publications: 13.
Rapamycin Therapy in Head and Neck Squamous Cell Carcinoma
ClinicalTrials.gov study NCT01195922. IPD Sharing: NO. Countries: 1. Publications: 3.
Preoperative Chemoradiotherapy and MK-3475 for Esophageal Squamous Cell Carcinoma (ACTS-29)
ClinicalTrials.gov study NCT02844075. IPD Sharing: NO. Countries: 1. Publications: 1.
Screening Trial of Nivolumab With Image Guided, Stereotactic Body Radiotherapy (SBRT) Versus Nivolumab Alone in Patients With Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
ClinicalTrials.gov study NCT02684253. IPD Sharing: Not stated. Countries: 1. Publications: 1.
ERBITUX® Followed by Adjuvant Treatment With Chemoradiation and ERBITUX® for Locally Advanced Head and Neck Squamous Cell Carcinoma
ClinicalTrials.gov study NCT01218048. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Study To Compare Avelumab In Combination With Standard of Care Chemoradiotherapy (SoC CRT) Versus SoC CRT for Definitive Treatment In Patients With Locally Advanced Squamous Cell Carcinoma Of The Head
ClinicalTrials.gov study NCT02952586. IPD Sharing: YES. Countries: 22. Publications: 1.
Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma
ClinicalTrials.gov study NCT03370276. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Cetuximab and Dasatinib in Recurrent Squamous Cell Carcinoma
ClinicalTrials.gov study NCT01488318. IPD Sharing: NO. Countries: 1. Publications: 2.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.